|
|
Please type responses here: |
|
First Name:
|
|
|
Last Name:
|
|
|
Email Address:
|
|
|
Retype Email Address:
|
|
|
Title:
|
|
|
Institution:
|
|
|
Phone Number:
|
|
|
City:
|
|
|
State/Province:
|
|
|
Postal/Zip Code:
|
|
|
Country:
|
|
|
What topics would you like to see covered in future POC Group Webinars?
|
|
|
Overall, how would you rate your satisfaction with this Point of Care Web Meeting?
|
Extremely satisfied
Very satisfied
Somewhat satisfied
Dissatisfied
|
|
Your feedback helps your webinar producers and sponsors improve the overall quality of their products and services.
|
|
What device types are you considering adding to your middleware system in 2023? Choose all that apply:
|
Blood Gas
Coagulation
Urinalysis
Hemoglobin
Flu
Strep
PT/INR
SARS-CoV
Manual Tests
Other
|
|
If you chose ‘other’ in the question above, please list the device type(s) are you considering adding to your middleware system in 2023:
|
|
|
What current data management system(s) are you using? Choose all that apply:
|
Abbott PrecisionWeb™
GEMweb® Plus
Orchard® Trellis™
Radiometer AQURE
Radiometer Radiance
RALS™ Connectivity System
Roche cobas® IT 1000 / cobas® infinity POC
SIEMENS POCcelerator™
SIEMENS RapidComm®
SIEMENS UniPOC™
Telcor QML®
None
Other
|
|
If you chose ‘other’ in the question above, please list your current data management system(s):
|
|
|
Do you currently use Cepheid tests?
|
Yes
No
|
|
Are you looking to add any new CLIA waived molecular tests this year?
|
Yes
No
|
|
Would you like to be contacted to learn more about Cepheid's POC solutions?
|
Yes
No
|
|
How familiar are you with the LumiraDx Platform?
|
0
1
2
3
4
5
6
7
8
9
10
|
|
Consider the following point-of-care viral testing options for upper respiratory infections. For testing during the respiratory season, which assay configuration would be most preferred by your institution:
|
Single test: multiplex simultaneous test for SARS-CoV-2 + Flu A/B + RSV
Two tests: a multiplex tests for SARS-CoV-2 + Flu A/B, and a separate RSV test
Three separate tests: (1) SARS-CoV-2 (2) Flu A/B, and (3) RSV test
Other
N/A
|
|
If you chose 'other' in the question above, please specify the assay configuration your institution would prefer:
|
|
|
Would you be interested in learning how the CLIA-waived CBC can help reduce lab send outs?
|
Yes
No
|
|
Will you be adding CLIA-waived tests to your practices within next 6 months?
|
Yes
No
|
|
Who do you currently purchase the majority of your products from? Please check all that apply:
|
Fisher HealthCare
Another Distribution Channel
Direct from Manufacturer
|
|
Which areas do you currently utilize POC testing for? Please check all that apply:
|
Flu
Group A Strep
Other Infectious Disease
Pregnancy
Coagulation (PT/INR)
Diabetes Monitoring (Glucose & HbA1c)
DOA
Lipid Panel
Other
I don’t do POC testing
|
|
Would you like to receive ASCLS PACE credit for this session, program number 174-003-23? (If no, you do not need to complete the following questions.)
|
Yes
No
|
|
To receive ASCLS PACE credit (PACE Program number 174-003-23, California Agency #0001) credit for "A Fresh Look at Reflexive Urine Testing" presented on February 23, 2023, you will be required to complete the following program evaluation.
|
|
If the following is true, please answer "Yes": I have attended the full instructional time for this program. I understand that completion of the program is necessary to receive the contact hours awarded for the program.
|
Yes
No
|
|
SPEAKER RATING
|
|
To what extent was the speaker knowledgeable, organized and effective during the presentation? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
Not applicable
|
|
To what extent did the speaker clarify and focus on the stated objectives? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
Not applicable
|
|
To what extent were the speaker's teaching methods & aids appropriate & effective? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
Not applicable
|
|
OBJECTIVES RATING:
To what extent was each objective achieved?
|
|
Compare the correlative performances of urinalysis, urine microscopy, and urine culture. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Describe motivations for and clinical outcomes associated with urine reflexive testing. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Contrast various laboratory workflows and operational considerations for implementing reflexive urine testing. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
PROGRAM CONTENT RATING
|
|
To what extent did the program content relate to the program's objectives? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Rate the contribution of this session to your overall knowledge of this subject. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Rate your overall degree of satisfaction with this session. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent).
|
1
2
3
4
|
|
Comments:
|
|
|
Thank you for attending this PACE approved program and completing this evaluation. Questions? Call Whitehat Communications at 434 202 8365.
|
|
|
